Semaglutide and LDL cholesterol: what changes at microdose range

Semaglutide's lipid story, in every phase 3 trial and every structured GLP-1 protocol, runs one direction: LDL, ApoB, and triglycerides go down. That's the number people expect when a repeat panel comes back. So when a small but recurring signal shows up in the microdosing community, LDL rising on doses well below the standard 0.25 mg starting point, it doesn't match anything published. That gap is worth naming plainly, not smoothing over.

What the trials and structured protocols actually show

Structured GLP-1 monitoring protocols track ApoB and a full lipid panel as core metabolic markers, and the expected direction is down: ApoB and triglycerides are expected to fall as insulin sensitivity and inflammation improve, with Lp(a) treated as a stable genetic baseline rather than something the drug moves. That's the model built for standard titration, and it holds at the lower end too. Sub-therapeutic ("microdose") semaglutide protocols run 0.1 to 0.25 mg weekly, occasionally up to 0.5 mg, and the documented expectation at that range is still anti-inflammatory (falling hs-CRP) and insulin-sensitizing. Nowhere in the structured protocol literature is a microdose expected to push LDL up. If it's happening, it's happening outside the model, not inside a known side effect.

Where the LDL-up reports are coming from

GLP-1 microdosing itself isn't standard of care. The clinical case for it, most visibly made by Dr. Tyna Moore, is coherent as a hypothesis (some people may be mildly GLP-1 deficient the way others are mildly thyroid- or progesterone-deficient) but it rests on anecdotal reporting and lacks controlled trials at that specific dose band. The FDA-approved, trial-backed dosing curve starts at 0.25 mg and ramps up over about 16 weeks. A quarter of that dose, drawn by hand with an insulin syringe because the brand pen can't go lower, has no equivalent trial arm. So an LDL increase reported at that range isn't contradicting an established finding. It's a data point in a range nobody has actually studied for lipid effects.

Three things to rule out before blaming the peptide

• No baseline. A single post-start LDL number proves nothing without a fasted lipid panel and ApoB drawn before the first dose. Most people microdosing informally never pull that baseline, which means there's no way to tell whether LDL actually moved, or was already there.
• The vial, not the peptide. Compounding pharmacy quality varies widely, and a gray-market or lightly-vetted source can differ from the labeled compound in ways a lipid panel wouldn't distinguish from a real drug effect. An LDL change could trace to what's actually in the vial rather than to semaglutide itself.
• Off-protocol dosing. Microdosing runs outside any titration curve with trial data behind it. That doesn't make an LDL change fake, it means there's no reference population to compare against, so a single self-reported case can't be read as a class effect yet.

What to actually do about it

If a repeat panel shows LDL moving the wrong way on a microdose, that's a pattern for your clinician to review against a real baseline, not something to self-diagnose from a single number. Pull (or request) the fasted lipid panel and ApoB result from before you started, run a same-lab retest, and bring both to whoever is managing the protocol. If there's no baseline on file, that's the first gap to close before drawing any conclusion about direction. The measurement stack that makes any of this attributable is the same one behind tracing other peptide side effects back to a cause, and the same vetting questions apply to the source of the compound itself. More on what we track and why is on the main feed.

FAQ

Does semaglutide normally raise or lower LDL cholesterol?

At the doses studied in trials and used in structured GLP-1 protocols, LDL and ApoB are associated with falling, not rising, alongside improved insulin sensitivity. A rise is not the expected direction at any dose with trial data behind it.

Is GLP-1 microdosing backed by clinical trials?

No. Microdosing (a fraction of the standard 0.25 mg starting dose) is an emerging, contested approach with a coherent rationale but no controlled trial data. It's an anecdotal clinical opinion, not standard of care.

How do I know if a peptide vial caused an LDL change?

You can't, from one number. A same-lab baseline lipid panel plus ApoB drawn before starting, and a retest afterward, is the minimum to attribute any change to the compound rather than to sourcing variability or normal fluctuation.

Should I stop microdosing if my LDL goes up on a retest?

That decision, and what it means for your protocol, belongs to your clinician working from your actual baseline and retest numbers. Bring both panels to that conversation rather than adjusting the dose on your own.